Reports
Sale
Global Acute Lung Injury Treatment Market Size, Share, Trends, Growth, Forecast: By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Others; By Injury Type: Direct Injury, Indirect Injury; By End User: Hospitals, Specialty Centres, Others; Regional Analysis; Market Dynamic; Supplier Landscape; Distribution Model; 2024-2032
Global Acute Lung Injury Treatment Market Outlook
The global acute lung injury treatment market size was valued at USD 3.19 billion in 2023, driven by the increasing prevalence of respiratory disorders across the globe. The market is anticipated to grow at a CAGR of 3% during the forecast period of 2024-2032 to achieve a value of USD 4.17 billion by 2032.
Acute Lung Injury: Introduction
Acute lung injury is a life-threatening medical condition which is caused by severe acute hypoxemic respiratory failure. It is considered to be a potential source of mortality and morbidity in critically ill patients who do not have any evidence of hydrostatic pulmonary oedema in them. The major symptoms in acute lung injury include severe shortness of breath, blood pressure, confusion, and extreme exhaustion, among others.
Acute lung injury (ALI), also known as acute respiratory distress syndrome (ARDS), is a serious and life-threatening condition, in which lungs get inflamed and damaged. The pathophysiology of acute lung injury involves an excessive immune response and inflammation in the lungs, leading to the disruption of the alveolar-capillary membrane and accumulation of fluid in the airspaces.
Global Acute Lung Injury Treatment Market Analysis
Acute lung injury is a common condition in which patients suffer from severe respiratory distress and lung inflammation. The incidence and prevalence of ALI are increasing across the globe due to factors like rising geriatric population, rising prevalence of chronic diseases, and increased awareness and diagnosis. Increasing focus on early and accurate diagnosis of acute lung injury is also contributing to the market growth.
Factors like increasing technological advancements in diagnostic techniques, such as imaging modalities (chest X-rays, CT scans), along with biomarker testing, enable better detection and monitoring, are further adding up to the global acute lung injury treatment market expansion.
The increasing demand for the launch of evidence-based practices and clinical trials that can guide treatment decisions and significantly improve patient outcomes, are expected to influence the global acute lung injury treatment market development. There is a significant rise in the integration of technology and digital solutions in acute lung injury treatment, which is transforming the management system for it. This technological integration involves the use of telemedicine and remote monitoring to enhance patient care, the adoption of electronic medical records for efficient data management, and the development of decision-support tools and algorithms for treatment optimization.
Global Acute Lung Injury Treatment Market Segmentations
Market Breakup by Therapy
- Mechanical Ventilation
- Pharmacotherapy
- Fluid Management
- Others
Market Breakup by Injury Type
- Direct Injury
- Indirect Injury
Market Breakup by End User
- Hospitals
- Specialty Centres
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Acute Lung Injury Treatment Market Overview
The rising prevalence of respiratory disorders, such as pneumonia, sepsis, and acute respiratory distress syndrome (ARDS), are directly contributing to the growing incidence of acute lung injury. Factors such as ageing populations, higher prevalence of chronic diseases, and environmental factors contribute to the increased burden of respiratory disorders. Increasing technological advancements in diagnostic techniques have improved the early detection and diagnosis of acute lung injury.
Imaging modalities like chest X-rays, CT scans, and ultrasound, along with biomarker testing, allow for more accurate and timely identification of ALI. This helps the patient in getting an appropriate and timely treatment. The increase in healthcare expenditures, along with the investments in healthcare infrastructure, are driving the growth of the global acute lung injury treatment market demand.
Governments and healthcare organizations across the globe are investing heavily in the healthcare sector to improve facilities and for promoting research and development in the field of respiratory care. The increasing demand for personalized medicine and precision facilities have been significantly contributing to the acute lung injury treatment market growth.
Additionally, the increased number in collaborations and research between academic-industry and healthcare sector is contributing in the identification of novel drug targets, testing new treatment approaches, and improving the overall understanding of the condition.
Global Acute Lung Injury Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bayer AG
- GSK plc.
- General Electric
- Koninklijke Philips N.V.
- Linde plc
- Medtronic
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- ONY Biotech Inc.
- Gilead Sciences, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy |
|
|
Breakup by Injury Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Acute Lung Injury Treatment Market Overview
3.1 Global Acute Lung Injury Treatment Market Historical Value (2017-2023)
3.2 Global Acute Lung Injury Treatment Market Forecast Value (2024-2032)
4 Global Acute Lung Injury Treatment Market Landscape
4.1 Global Acute Lung Injury Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Acute Lung Injury Product Landscape
4.2.1 Analysis by Therapy
4.2.2 Analysis by Injury Type
5 Global Acute Lung Injury Treatment Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Acute Lung Injury Treatment Market Segmentation
6.1 Global Acute Lung Injury Treatment Market by Therapy
6.1.1 Market Overview
6.1.2 Mechanical Ventilation
6.1.3 Pharmacotherapy
6.1.4 Fluid Management
6.1.5 Others
6.2 Global Acute Lung Injury Treatment Market by Injury Type
6.2.1 Market Overview
6.2.2 Direct Injury
6.2.3 Indirect Injury
6.3 Global Acute Lung Injury Treatment Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Specialty Centres
6.3.4 Others
6.4 Global Acute Lung Injury Treatment Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Acute Lung Injury Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Acute Lung Injury Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Acute Lung Injury Treatment Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Acute Lung Injury Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Acute Lung Injury Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Bayer AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 GSK plc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 General Electric
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Koninklijke Philips N.V.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Linde plc
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Medtronic
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Pfizer Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Teva Pharmaceutical Industries Ltd.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 ONY Biotech Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Gilead Sciences, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Global Acute Lung Injury Treatment Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 3.19 billion in 2023, driven by the rising prevalence of eye disorders.
The market is anticipated to grow at a CAGR of 3% during the forecast period of 2024-2032 and reach a market value of USD 4.17 billion by 2032.
The higher prevalence of chronic diseases and environmental factors contribute to the increasing burden of respiratory disorders across the globe, which directly influence the market.
The increasing technological advancements in imaging modalities, along with biomarker testing are enabling the better detection and monitoring of acute lung injury owing to the market expansion.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the regional market.
The different therapies in the market include mechanical ventilation, pharmacotherapy, and fluid management, among others.
The injuries in the market can be categorised into direct injury and indirect injury.
The end users of the market can be categorised into hospitals and specialty centres, among others.
Key players in the market can be categorised into Bayer AG, GSK plc., General Electric, Koninklijke Philips N.V., Linde plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., ONY Biotech Inc., Gilead Sciences, Inc., and Medtronic.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER